Treatment-Related Change Versus Tumor Recurrence in High-Grade Gliomas: A Diagnostic Conundrum—Use of Dynamic Susceptibility Contrast-Enhanced (DSC) Perfusion MRI

Distinguishing Recurrent High-grade Gliomas from Radiation Injury

(2011) Sotirios Bisdas et al.   ACADEMIC RADIOLOGY

Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status

(2011) D.-S. Kong et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

T1- and T2*-Dominant Extravasation Correction in DSC-MRI: Part II—Predicting Patient Outcome after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2011) Kyrre E Emblem et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Early Evaluation of Tumoral Response to Antiangiogenic Therapy by Arterial Spin Labeling Perfusion Magnetic Resonance Imaging and Susceptibility Weighted Imaging in a Patient With Recurrent Glioblastoma Receiving Bevacizumab

(2011) Slim Fellah et al.   JOURNAL OF CLINICAL ONCOLOGY

Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI

(2010) Yong Hwy Kim et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Potential for Differentiation of Pseudoprogression From True Tumor Progression With Dynamic Susceptibility-Weighted Contrast-Enhanced Magnetic Resonance Imaging Using Ferumoxytol vs. Gadoteridol: A Pilot Study

(2010) Seymur Gahramanov et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma

(2010) Christina Tsien et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53

(2010) Hyun-Cheol Kang et al.   JOURNAL OF NEURO-ONCOLOGY

Changes in Relative Cerebral Blood Volume 1 Month after Radiation-Temozolomide Therapy Can Help Predict Overall Survival in Patients with Glioblastoma

(2010) Rajiv Mangla et al.   RADIOLOGY

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging

(2009) Jennifer L. Clarke et al.   Current Neurology and Neuroscience Reports

Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target

(2009) Randy L. Jensen   JOURNAL OF NEURO-ONCOLOGY

Magnetic Resonance Perfusion and Permeability Imaging in Brain Tumors

(2009) Saulo Lacerda et al.   NEUROIMAGING CLINICS OF NORTH AMERICA

Posttreatment Recurrence of Malignant Brain Neoplasm: Accuracy of Relative Cerebral Blood Volume Fraction in Discriminating Low from High Malignant Histologic Volume Fraction

(2009) Emerson L. Gasparetto et al.   RADIOLOGY

Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging

(2009) Ramon F. Barajas et al.   RADIOLOGY

Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements

(2008) L.S. Hu et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

(2008) A. Desjardins et al.   CLINICAL CANCER RESEARCH

Pseudoprogression in Glioblastoma

(2008) Marc C. Chamberlain   JOURNAL OF CLINICAL ONCOLOGY

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Comparison of Dynamic Susceptibility-weighted Contrast-enhanced MR Methods: Recommendations for Measuring Relative Cerebral Blood Volume in Brain Tumors

(2008) Eric S. Paulson et al.   RADIOLOGY